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a b s t r a c t
Neurodegeneration with brain iron accumulation (NBIA) deﬁnes a heterogeneous group of
progressive neurodegenerative disorders characterized by excessive iron accumulation in
the brain, particularly affecting the basal ganglia. In the recent years considerable develop-
ment in the ﬁeld of neurodegenerative disorders has been observed. Novel genetic methods
such as autozygosity mapping have recently identiﬁed several genetic causes of NBIA. Our
knowledge about clinical spectrum has broadened and we are now more aware of an overlap
between the different NBIA disorders as well as with other diseases. Neuropathologic point
of view has also been changed. It has been postulated that pantothenate kinase-associated
neurodegeneration (PKAN) is not synucleinopathy. However, exact pathologic mechanism
of NBIA remains unknown. The situation implicates a development of new therapies, which
still are symptomatic and often unsatisfactory. In the present review, some of the main
clinical presentations, investigational ﬁndings and therapeutic results of the different NBIA
disorders will be presented.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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journal homepage: http://www.elsevier.com/locate/pjnnsNeurodegeneration with brain iron accumulation (NBIA) deﬁnes
a heterogeneous group of progressive neurodegenerative
disorders characterized by excessive iron accumulation in the
brain, particularly affecting the basal ganglia [1]. The pantothe-
nate kinase-associated neurodegeneration (PKAN, previously
named as Hallervorden–Spatz disease) and PLA2G6-associated
neurodegeneration (PLAN) are the two main syndromes.
Furthermore, novel genetic methods such as autozygosity
mapping have recently identiﬁed several other genetic causes
of NBIA [2] (Table 1). NBIA syndromes pose a challenge to the
clinicians due to their complex phenomenology as well as their
requirement for a comprehensive treatment. This review was* Corresponding author at: Department of Neurology, Przybyszewskieg
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0028-3843/# 2014 Polish Neurological Society. Published by Elsevier Uprompted by the considerable development in this ﬁeld. Some
of the main clinical presentations, investigational ﬁndings and
therapeutic results of the different NBIA disorders will be
presented in the following review.
1. Pantothenate kinase-associated
neurodegeneration (PKAN) – NBIA Type 1
The major form of NBIA is pantothenate kinase-associated
neurodegeneration (PKAN), previously known as Hallervor-
den–Spatz disease (HSD). HSD was ﬁrst described by theo 49, 60-355 Poznan, Poland. Tel.: +61 869 15 35; fax: +61 8691697;
-Domaszewicz).
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Table 1 – Neurodegeneration with brain iron accumula-
tion (NBIA) [2,79,80].
NBIA Mutated
gene
Chromosomal
localization
Pantothenate kinase-associated
neurodegeneration
(PKAN)/NBIA1b
PANK2a 20p13
PLA2G6-associated
neurodegeneration
(PLAN)/NBIA2, PARK14
PLA2G6c 22q12
Aceruloplasminemia (Acp) CPd 3q23
Neuroferritinopathy FTLe 19q13
FA2H – Associated
Neurdegeneration
(FAHN)/SPG35g
FA2Hf 16q23
Kufor-Rakeb Disease
NBIA3/(PARK9)
ATP13A2 1p36
Mitochondrial membrane
protein associated
neurodegeneration (MPAN)
C19orf12 19q12
Static encephalopathy of
childhood with
neurodegeneration
in adulthood (SENDA
syndrome)
nkh nk
a Pantothenate kinase 2.
b Neurodegeneration with brain iron accumulation.
c Phospholipase A2.
d Ceruloplasmin.
e Ferritin light chain.
f Fatty acid 2-hydroxylase.
g Spastic paraplegia.
h Not known.
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Spatz in 1922 [3]. It should be stressed that because of their
criminal activities during World War II (participating in Nazi
T4 program of euthanasia), HSD is now referred to as PKAN [4].
PKAN is an autosomal recessive disorder caused by mutations
in PANK2 gene [5] which is located on chromosome 20p [6]. The
exact pathologic mechanism of PKAN remains unknown.
PANK2 encodes pantothenate kinase 2, which is a regulatory
enzyme in the coenzyme A (CoA) biosynthesis and catalyzing
the phosphorylation of pantothenate (vitamin B5), N-pan-
tothenoyl-cysteine, and pantetheine. CoA plays an essential
role in fatty acid synthesis and energy metabolism. It has been
postulated that decreased level of panthotenate kinase 2 leads
to the accumulation of cysteine-containing neurotoxic sub-
strates, mostly in the regions with higher energy demand,
such as the basal ganglia [1,5]. Excess amounts of cysteine,
chelate iron and form a complex which leads to tissue damage
by promoting oxidative stress [7]. PKAN accounts for approxi-
mately 50% of cases of NBIA [1]. According to the time of onset,
PKAN has been classiﬁed as early onset, rapidly progressive
classic disease and late onset, slowly progressive atypical
variant.
2. Classic PKAN
In the classic form, onset occurs between 3 and 4 years of age.
Extrapyramidal dysfunction with prominent dystonia as wellas gait and postural difﬁculties are usually the most prominent
syndromes [1] with early involvement of oromandibular
region by dystonic symptoms and signs [8]. Moreover,
parkinsonism, chorea, acanthocytosis, cognitive decline and
dementia might be present. Other common features include
involvement of the corticospinal tract with spasticity, hyper-
reﬂexia and pathologic signs, dysarthria and clinical or
electroretinographic evidence of pigmentary retinopathy
[1,9]. Egan et al. demonstrated that Adie's-like pupils, vertical
saccades, and saccadic pursuits are common, what suggests
that midbrain degeneration frequently occurs in PKAN.
Additionally, square wave jerks, poor convergence, abnormal
vertical optokinetic response and inability to suppress the
vestibule-ocular reﬂex may be present. There was no evidence
of optic atrophy [10]. Supranuclear gaze palsy has also been
reported in PKAN patient [11]. The loss of ambulation occurs
within 10–15 years after the onset of the disease [1].
3. Atypical PKAN
The onset takes place between the second and the third
decades [1]. Atypical disease is clinically heterogeneous [12].
Speech difﬁculties (palilalia, dysarthria) and psychiatric
problems are frequent the initial syndromes. Extrapyramidal
features are generally less severe and more slowly progressive
than patients with classic form [1,7]. It has been reported that
patients with adult onset PKAN often present parkinsonism as
the ﬁrst sign whereas early onset individuals seem to have
dystonia as a presenting feature [7]. Psychiatric syndromes
include personality changes with impulsivity and violent
outbursts, depression, obsessive-compulsive signs and emo-
tional lability [13,14]. The presence of psychotic symptoms has
also been described in the literature [15–18]; cognitive decline
and dementia may also develop [1]. Moreover, pyramidal tract
involvement [12], freezing during ambulation and pure
akinesia can be observed [19,20]. Sleep analysis revealed
altered sleep architecture with reduced total time of sleep and
the lack of slow wave sleep. No signiﬁcant apnea/hypopnea
and REM sleep abnormalities – in particular REM sleep
behavior disorders were detected [21]. Diagnostic criteria for
PKAN were ﬁrst proposed by Dooling et al. and based on
clinical features [22]. Swaiman revised these after brain MRI
became a valuable diagnostic tool [23,24]. Gregory et al. suggest
that after identiﬁcation of PANK2 gene and the development of
the molecular diagnostic tests, obligate and corroborative
features should be improved again [25] (Table 2). The
development of high-ﬁeld magnetic resonance imaging
(MRI) in the 80-ties was a signiﬁcant milestone in the further
studies of NBIA. Brain MRI allowed for noninvasive demon-
stration of decreased T2 relaxation time caused by iron
deposition, what correlates with iron accumulation of the
brain in postmortem studies. Thus, MRI has become a highly
sensitive diagnostic tool for the diagnosis of NBIA [26]. An ‘‘eye
of the tiger’’ sign, ﬁrst described by Sethi et al. in 1988 is a
speciﬁc MRI pattern, a key diagnostic feature of PKAN [27]. It is
high signal intensity in the center of the globus pallidus
interna with low signal intensity in the surrounding region.
The surrounding hypointensity of the globus pallidus repre-
sents excess iron deposition and the central hyperintensity is
Table 2 – Diagnostic criteria for PKAN proposed by
Swaiman and Dooling et al. [22–24].
Obligate features Corroborative features
Onset in the ﬁrst three decades Corticospinal tract
involvement
Progression of signs and symptoms Progressive intellectual
impairment
Evidence of extrapyramidal
dysfunction (dystonia, rigidity,
tremor, bradykinesia,
choreoathetosis)
Retinitis pigmentosa,
optic atrophy
T2-weighted brain MRI: high signal
intensity in the center of the
globus pallidus interna with low
signal intensity in the surrounding
region (eye of the tiger sign)
Family history of similar
disorder
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changes may precede clinical onset [29]. In the early stages of
PKAN only isolated high signal intensity on T2-weighted
images of the globus pallidus interna can be observed [26].
Hayﬂick et al. emphasized that there is an absolute correlation
between ‘‘eye of the tiger’’ sign and presence of mutations in
PANK2 [1,30]. However, similar changes in MRI were described
in many other conditions and these should be taken into
consideration in the differential diagnosis, when appropriate
(Fig. 1). This characteristic pattern was also observed in
neuroferritinopathy. However, in these cases the involvement
of other basal ganglia nuclei (caudate and putamen), thalamus
and cerebral cortex was found and it is not seen in PKAN [31].
Moreover, ‘‘eye of the tiger’’ can be seen in non-NBIA
conditions such as corticobasal degeneration [32], progressive
supranuclear palsy [33] and multiple system atrophy [34].
Hypointensities of the globus pallidus, caudate nuclei, and
putamen on T2 images have been described in beta-thalassa-
nemia major [35], HIV infection [36], Wilson disease [37], toxic
and metabolic degeneration [26]. Therefore, MR images should
be scrutinized in the context of clinical data and otherFig. 1 – Examples of brain MR imaging in NBIA disorders. On th
(PKAN), in the middle, Kufor-Rakeb disease (due to ATP13A2 mu
the right. In PKAN there is a classic eye-of the-tiger sign. Iron acc
Rakeb disease patient. In this gene-proven neuroferritinopathy p
slight hint of thalamic involvement.
Image reprinted with permission from John Wiley and Sons: Scradiological ﬁndings. In later stages of the disease only
hypointesity of the globus pallidus may be seen. This might
be explained by further accumulation of iron deposits, which
can obscure central hyperintensity [38]. Historically, all
patients who had HSD/NBIA phenotype and radiological
evidence of excess iron accumulation in the globus pallidus
were diagnosed of PKAN. After the identiﬁcation of mutations
in the PANK2 gene on chromosome 20p12.3–p13 the term
pantothenate kinase-associated neurodegeneration (PKAN)
has been proposed only for patients with conﬁrmed or
suspected mutations in PANK2. For the remainder the term
‘‘neurodegeneration with brain iron accumulation’’ has been
suggested [1]. Mutations (mainly missense) as well as dele-
tions, duplications and splice-site ones have been detected in
all seven exons of PANK2 [39]. Mutations in PANK2 occur in all
cases of classic PKAN, especially in those with ‘‘eye of the tiger
sign’’ on brain MR and around one third of cases with atypical
features [1]. While mutations in patients with classic disease
usually lead to protein truncation, those in atypical patients
often result in amino acid changes. It indicates that many of
patients with atypical form of disease may have a residual
panthotenate kinase 2 activity [1]. Two most frequent
mutations (1231G > A, 1253C > T) account for about one third
of all cases and the majority of the remaining carry ‘‘private
mutations’’ [30]. It is noteworthy that G411R mutation was
detected on only one chromosome in few cases. It suggests
that G411R might act in semidominant fashion, with one allele
sufﬁcient to cause disease [1].
Transcranial sonography revealed bilateral hyperechogeni-
city restricted to the globus pallidus and substantia nigra (SN),
what correlates with the hypointense regions detected during
MR examinations [40]. Dopamine transporter (DaT) and cardiac
123I-meta-iodobenzylguanidine (MIBG) SPECT imaging are
generally within normal limits [41,42]. A recent neuropatholog-
ical study in 6 genetically conﬁrmed cases of PKAN demon-
strates that mainly central nervous system is occupied with
occasional peripheral manifestations of the disease, i.e.
testicular pathology, lipid proﬁle abnormalities, acanthocytosis.e left, pantothenate kinase-associated neurodegeneration
tations), and neuroferritinopathy (due to FTL mutations) on
umulation affected the putamen and caudate in our Kufor-
atient, there was iron deposition in the basal ganglia, with a
hneider et al. [2].
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but adjacent structures (medial putamen, internal capsule) and
subcortical white matter also could be involved. The most
prominent microscopical ﬁnding includes iron deposition,
neuronal degeneration and the presence of widely disseminat-
ed, rounded or oval structures termed spheroids. Two types of
spheroids have been distinguished: smaller, eosinophilic
spheroidal structures as a substrate of dystrophic neurons;
and larger, reﬂecting degenerating neurons. Iron accumulation
was observed in the globus pallidus within the cytoplasm of
neurons, glia and macrophages, especially in a perivascular
distribution. Increased diffusely in the neuropil of the globus
pallidus ('iron dust') was also present [43]. Numerous previous
articles reported that PKAN could be characterized as both
synucleinopathy and tautopathy. However, Kruer et al. in the
recent studies performed in gene-proven patients have not
conﬁrmed presence of Lewy bodies, neuroﬁbrillary tangles and
tau-positive neuritis [43]. This discrepancy could result from the
fact that many histological studies were performed before
identiﬁcation of the PANK2 gene. Thus, it is possible that some of
the historical ‘‘Hallervorden–Spatz disease’’ cases with Lewy
body pathology may actually not have had PKAN, but at least
another form of NBIA [43]. In the latest study Li et al. also
conﬁrmed that PKAN is not synucleinopathy, however de-
scribed one autopsy case of signiﬁcant tau pathology compris-
ing neuroﬁbrillary tangles and neuropil threads [44]. The
treatment for NBIA disorders is challenging and requires a
comprehensive approach to the patients. However, it still
remains symptomatic. Most NBIA patients do not respond well
to levodopa administration. However, in reducing abnormal
movements and spasticity several drugs may be efﬁcacious,
including benzodiazepines, anticholinergics, baclofen, typical
and atypical neuroleptics, botulinum toxin injection and
intrathecal baclofen [30]. Deep brain stimulation (DBS) of the
internal globus pallidus may produce some beneﬁt, especially in
the patients with PKAN, but results are variable [45,46].
Supplementing of pantothenic acid seemed to be effective in
drosophila models of PKAN, but results for human trials are not
yet available [47].
4. PLA2G6-associated neurodegeneration
(PLAN) – NBIA Type 2
PLA2G6-Associated Neurodegeneration (PLAN) is a result of
mutations in the PLA2G6 gene, which encodes a calcium-
independent phospholipase A2 (iPLA2-VIa) [48]. Phospholipase
A2 enzymes catalyze the hydrolysis of glycerophospholipids,
generating a free fatty acid (mainly arachidonic acid) and a
lysophospholipid, which are thought to play a crucial role in
cell membrane homeostasis, signal transduction, cell prolif-
eration and apoptosis. Thereby defects in iPLA2-VIa cause
cellular membrane abnormalities which lead to pathological
changes and eventually culminating in progressive neurologi-
cal impairment [49].
Depending on age two clinical phenotypes can be distin-
guished- infantile neuroaxonal dystrophy (INAD) and atypical
neuroaxonal dystrophy (atypical NAD). INAD usually occurs
before the lapse of 2 years and progressive psychomotor
decline is the most frequent presentation. Characteristicfeatures also include cerebellar ataxia, gait impairment, visual
disturbances due to optic atrophy, truncal hypotonia and
pyramidal signs. Fast rhythms on an EEG and general seizures
may, also, be present [1]. The clinical spectrum of late-onset
PLAN is not as well characterized and includes progressive
dystonia, parkinsonism, cognitive impairment, psychiatric
features and optic atrophy [50]. Karak syndrome described by
Mubaidin et al. as a novel degenerative disorder of the basal
ganglia and cerebellum [51] has been shown to be caused by
mutations in PLA2G6 and falls into the spectrum of atypical NAD
[48]. In the early stage of INAD neuroimaging shows cerebellar
atrophy. T2-weighted MR demonstrates hypointensity of globus
pallidus, dentate nuclei, and substantia nigra, which reﬂects
iron depositions [31]. However, iron accumulation may be
absent, and MRI can be even normal. In addition, cortical
atrophy and white matter changes can also occur [50].
Pathological studies demonstrated neuroaxonal dystrophy,
alpha-synuclein pathology with Lewy bodies and Lewy neurites.
Lewy body pathology was particularly severe in the neocortex,
basal forebrain, hippocampal formation and brainstem nuclei.
The ﬁndings of Lewy body pathology in PLA2G6 strenghten a
link with other neurodegenerative diseases such as Parkinson's
disease and dementia with Lewy bodies. Cerebellar atrophy
may be present and with iron accumulation in the globus
pallidus is highly speciﬁc for INAD. The accumulation of
hyperphosphorylated tau also been reported [52,53].
5. Aceruloplasminemia (aCP)
Aceruloplasminemia (aCP) is an autosomal recessive disorder
caused by mutations in the ceruloplasmin gene (CP), on
chromosome 3q [54,55]. Ceruloplasmin plays an essential role
in the mobilization of iron from tissues through its ferroxidase
activity and carries 95% of plasma copper. Protein dysfunction
resulted in excessive iron accumulation in the brain (basal
ganglia, nuclei, thalami, dentate nuclei and cerebral and
cerebellar cortices), liver and pancreas [56]. The classical triad
of aCP include young-adult onset diabetes mellitus, retinal
degeneration and various neurological symptoms [54]. Mean-
onset age is around 50, with prominent extrapyramidal features
and cognitive impairment. Cerebellar ataxia is also frequent
sign [55]. Laboratory ﬁndings typically reveal undetectable
ceruloplasmin in the serum, low levels of serum copper and iron
and elevated serum ferritin [31]. T2-weighted brain MRI scans
showed widespread hypointensity in the cerebral cortex, globus
pallidus, putamen, caudate, thalamus, dentates, substantia
nigra, and cerebellar cortex [31]. Treatment for aCP remains
symptomatic. Several studies have reported positive results of
treating aceruloplasminemia with iron-chelating agents such
as desferrioxamine mesylate [57] and deferasirox [55]. Admin-
istration of an anti-oxidative drugs like deferiprone has also
been suggested. However, systematic studies are needed to
assess the efﬁcacy of these therapies [58].
6. Neuroferritinopathy
Neuroferritinopathy (also known as hereditary ferritinopathy)
is a result of ferritin light chain (FTL) gene mutations. In
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dominant. Onset begins around the age of 40. The clinical
presentation is characterized by extrapyramidal features
including chorea and dystonia [59]. MRI may reveal consistent
involvement of the dentate nuclei, globus pallidus, and
putamen, with areas of hyperintensity due to probable
cavitation, involving the pallida and putamen [31]. Laboratory
tests show decreased level of serum ferritin. Pathology
assessment shows severe neuronal loss in the basal ganglia,
atrophy of cerebellum and cerebral cortex, abnormal iron
accumulation and the presence of ferritin inclusion bodies
(IBs) in neurons and glia [60]. Ferritin IBs can also be seen in
hepatocytes, cells of the renal tubular epithelium, endothelial
cells of capillaries, and skin ﬁbroblasts [61,62]. Effective
treatment still remains unknown. Focal botulin toxin injec-
tions and oral antioxidant therapy can be beneﬁcial, but this
approach requires further studies [63].
7. FA2H-associated neurodegeneration
(FAHN)/SPG35
Autosomal recessive FA2H-Associated Neurodegeneration
(FAHN) results from the mutations in the fatty acid hydroxy-
lase gene, FA2H [64]. FA2H plays a role in the metabolism of
myelin sheaths [65]. It produces free 2-hydroxy fatty acids
necessary for the biosynthesis of ceramide, galactosylcera-
mide and sulfatide, which are major constituents of normal
CNS myelin [66]. Mutations in the FA2H gene had previously
been associated with progressive familial leukodystrophy and
hereditary spastic paraplegia (SPG35). The clinical phenotype
is characterized by childhood- onset gait impairment with
prominent spastic quadriplegia, pyramidal tract signs, pro-
found ataxia and dystonia. Moreover, optic atrophy, nystag-
mus, acquired strabismus and seizures may be present. In
general, clinical presentation discussed above demonstrated
similar features to those observed in neuroaxonal dystrophy
(NAD) [64]. T2-weighted MR shows bilateral hypointensities of
the globus pallidus compatible with excess iron deposits,
prominent pontocerebellar atrophy, mild generalized cortical
atrophy, thin corpus callosum and conﬂuent periventricular
white matter T2 hyperintensities [64]. It is noteworthy that
white matter abnormalities are hallmark feature of leukodys-
trophies and thin corpus callosum is a core element of some
types of hereditary spastic paraplegia [67]. Deterioration of
lipid and ceramide metabolism caused by FA2H deﬁciency is
the common pathologic mechanism of NBIA, HSP and
leukodystrophies. Thus, the clinical and radiological overlap
between these diseases is not surprising. Overall, FA2H
mutations result in a clinical spectrum rather than distinct
disorders [68]. Neuropathological studies are still awaited.
8. Kufor-Rakeb disease (PARK9)
Kufor-Rakeb disease is an autosomal recessive extrapyramidal-
pyramidal syndrome, originally described in the consanguine-
ous Jordanian family from the village Kufor-Rakeb [69]. It is
caused by mutations in ATP13A2 gene [70], which is localized on
chromosome 1p36 [71]. ATP13A2 encodes a lysosomal 5 P-typeATPase and in the human brain, it is localized on pyramidal
neurons within cerebral cortex and dopaminergic neurons in
the substantia nigra [72]. In the recent study Park et al.
demonstrated several different mechanisms by which muta-
tions in ATP13A2 may contribute to the development of Kufor-
Rakeb disease. First, mutant ATP13A2 can lead to impaired
lysosomal function and this effect may result in the cellular
accumulation of toxic and unnecessary proteins such as a-
synuclein. Moreover, the mutant proteins are degraded by
proteasomal, not the lysosomal pathway. It might overload
proteasomal pathway and handicap its normal function to
degrade other proteins, particularly if the lysosomal pathways
are not working efﬁciently. The third mechanism includes
impaired ion transportation or ionic imbalance that results in
increased oxidative stress in the cell [73]. Characteristic clinical
features include juvenile-onset, levodopa-responsive parkin-
sonism, pyramidal dysfunction and eye movements abnormal-
ities with supranuclear gaze palsy. Slowing of vertical and
horizontal saccades and saccadic pursuit may be present [74]. A
good response to levodopa is transient and levodopa-dyskine-
sias tend to develop early [75]. Cognitive deterioration and overt
dementia have been described [70]. Brain MR images reveal
generalized brain atrophy affecting both cerebral and subcorti-
cal structures and hypointensities of the putamen and caudate
nuclei, reﬂecting iron deposition, however neuropathological
conﬁrmation is still awaiting [76]. Dopamine transporter
imaging demonstrated bilateral symmetrical reduction of
striatal activity indicative of diminished presynaptic function.
Transcranial sonography of the SN remained within normal
limits. Electrophysiological studies showed pyramidal tract
damage [77].
9. Mitochondrial membrane protein
associated neurodegeneration (MPAN)
Extensive studies led to identiﬁcation of a new mutation
causing a neurodegeneration with brain iron accumulation.
Hartig et al. described a Polish cohort whose clinical phenotype
was characterized by progressive spasticity, dystonia, optic
atrophy, motor axonal neuropathy, and psychiatric signs. T2-
weight MR showed bilateral hypointensity of the globus
pallidus and substantia nigra. A histopathological examina-
tion in a single autopsy case detected Lewy bodies, tangles,
spheroids, and tau pathology. Mutation in the gene C19orf12 on
chromosome 19 was revealed. The acronym MPAN (Mitochon-
drial Membrane Protein Associated Neurodegeneration) has
been proposed [78].
10. Static encephalopathy of childhood with
neurodegeneration in adulthood (SENDA
syndrome)
Recently a static encephalopathy of childhood with neurode-
generation in adulthood (SENDA syndrome) was described.
Genetic cause is still unknown. The clinical presentation is
characterized by early onset spastic paraplegia and cognitive
impairment which remains static until the late 20s to early 30s
but then progresses to parkinsonism and dystonia. Moreover,
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malities and dysautonomia may be present. Brain MRI
revealed iron accumulation in the globus pallidus, hypointen-
sities in the substantia nigra and white matter changes. A good
response to levodopa was noticed [79].
11. Conclusions
We have summarized the major genetic causes and clinical
heterogeneity of NBIA. It is worth pointing out that considerable
developments in the ﬁeld of neurodegenerative disorders are
being witnessed. However, the exact pathophysiology of NBIA is
still poorly understood. In order to develop new therapies,
which still remain symptomatic and often unsatisfactory, it is
crucial to better understand the pathologic mechanism, clinical
course and diagnostic criteria of the distinct NBIA syndromes.
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